Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice,Amyloid

当前位置： X-MOL 学术 › Amyloid › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice
Amyloid ( IF 5.5 ) Pub Date : 2024-02-13 , DOI: 10.1080/13506129.2024.2313218
Antonia S. Carroll _{1,

2} , Yousuf Razvi ₃ , Luke O’Donnell ₂ , Elena Veleva ₄ , Amanda Heslegrave _{4,

5} , Henrik Zetterberg _{4,

5,

6,

7,

8} , Steve Vucic ₉ , Matthew C. Kiernan ₁ , Alexander M. Rossor ₂ , Julian D. Gillmore ₃ , Mary M. Reilly ₂

Affiliation

Brain and Mind Centre, Faculty of Medicine and Health, Translational Research Collective University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia
Centre for Neuromuscular disease, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, UK
UK Dementia Research Institute at UCL, London, UK
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
Brain and Nerve Research Centre, Concord Hospital, University of Sydney, Sydney, Australia

Neurofilament light chain (NfL) has emerged as a sensitive biomarker in hereditary transthyretin amyloid polyneuropathy (ATTRv-PN). We hypothesise that NfL can identify conversion of gene carriers ...

中文翻译：